Utility of Inhaled Antibiotics in Children with Exacerbations of Non-Cystic Fibrosis Bronchiectasis: A Pilot Study
Wan Theng Goh, Shih Ying Hng, Mohamad Shafiq Azanan, Kah Peng Eg, Quraisiah Adam, Qiao Yun Lee, Jessie Anne de Bruyne, Anna Marie NathanAbstract
Background:
Inhaled antibiotics are an accepted treatment strategy in cystic fibrosis. We aimed to explore the effect of inhaled antibiotics with and without systemic antibiotics in children experiencing an exacerbation of non-cystic fibrosis bronchiectasis (NCFBE).
Methods:
This prospective pilot study included children with an exacerbation of NCFBE. Inhaled antibiotics were prescribed based on the bacterial antibiogram for 3 months or 1 month if they had a tracheostomy. Systemic antibiotics were prescribed at the physician’s discretion. We assessed respiratory bacterial culture and Parent Cough-specific Quality-of-Life (PC-QoL) and cough scores at recruitment, after 3 months of treatment, and 3 months postcessation of treatment.
Results:
Thirty-seven participants were recruited with a median (interquartile range) age of 3.19 (1.55, 6.74) years. One-quarter (
Conclusion:
Inhaled antibiotics alone are not effective in managing children with exacerbations of NCFBE.